Is there a decline in the vascular event rate after transient ischemic attack or stroke in antiplatelet trials?

Cerebrovascular Diseases

Volumn 28, Issue 5, 2009, Pages 439-447

  Lemmens, Robin ^a   Chen, Feng ^b,e   Ni, Yicheng ^b   Fieuws, Steffen ^c   Thijs, Vincent ^a,d  

^a Department of Neurology ^*  (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

Antithrombotic therapy; Aspirin; Vascular event rate

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; WARFARIN;

ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

AGED; ASPIRIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 69749096459     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235988     Document Type: Article

References (56)

1. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
2. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
3. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F: Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double-blind, aspirincontrolled trial. Stroke 2008; 39: 1827-1833.
4. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ: Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107-116.
5. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-2448.
6. Marti-Fabregas J, Cocho D, Marti-Vilalta JL, Gich I, Belvis R, Bravo Y, Millan M, Castellanos M, Rodriguez-Campello A, Egido J, Geffner D, Gil-Nunez A, Marta J, Navarro R, Obach V, Palomeras E: Aspirin or anticoagulants in stenosis of the middle cerebral artery: a randomized trial. Cerebrovasc Dis 2006; 22: 162-169.
7. Hackam DG, Spence JD: Combining multiple approaches for the secondary prevention of vascular events after stroke. A quantitative modeling study. Stroke 2007; 38: 1881-1885.
8. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR: Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 2005; 330: 1179.
9. Sharp S: Meta-analysis regression. Stata Tech Bull 1998; 42: 16-24.
10. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451.
11. Grotemeyer KH, Evers S, Fischer M, Husstedt IW: Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double- blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci 2000; 181: 65-72.
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
13. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
14. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA: Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
15. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978; 299: 53-59.
16. Persantine Aspirin Trial in cerebral ischemia. 2. Endpoint results. The American- Canadian Co-operative Study Group. Stroke 1985; 16: 406-415.
17. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke 1987; 18: 325-334.
18. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UKTIA Study Group. Br Med J (Clin Res Ed) 1988; 296: 316-320.
19. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345-1349.
20. A comparison of two doses of aspirin (30 vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991; 325: 1261-1266.
21. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ: 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14. (Pubitemid 13174990)
22. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P: Danish verylow- dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211-1215.
23. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G: A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982; 13: 175-179.
24. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J: Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 h after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. J Med Assoc Thai 2005; 88(suppl 3):S148-S154.
25. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E: Triflusal vs. aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004; 62: 1073-1080.
26. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
27. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8: 301-314.
28. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. 2. Surgical group. Stroke 1978; 9: 309-319.
29. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J: Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke 1983; 14: 677-681.
30. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947-2957.
31. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R: Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial. Rev Neurol (Paris) 1982; 138: 367-385.
32. Hass WK, Easton JD, Adams HP Jr, Pryse- Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-507. (Pubitemid 19203874)
33. Lee TK, Chan KW, Huang ZS, Ng SK, Lin RT, Po HL, Yuan RY, Lai ML, Chang TW, Yan SH, Deng JC, Liu LH, Lee KY, Lie SK, Sung SM, Hu HH: Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. Thromb Res 1997; 87: 215-224.
34. Li Y, Li D, Wang L: A prospective randomized controlled study on ticlopidine with aspirin for the prevention of ischemic cerebral stroke. J Clin Neurol 2000; 13: 146-148.
35. Li YZ, Li DN, Hu ZQ, Fan RY, Liu BM, Zhu SW, Cheng GZ, Wang SJ, Li CG, Zheng JL, Zhang SG, Ma RZ, Hu ZK, Cui BW, Chi HW: Multicenter controlled trial of aspirin in secondary prevention of ischemia cerebrovascular disease in aged. Chin J Prev Control Chronic Noncommun Dis 1997; 5: 221-224.
36. Marti Masso JF, Lozano R: Nicardipine in the prevention of cerebral infarction. Clin Ther 1990; 12: 344-351.
37. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34: 840-848.
38. Reuther R, Dorndorf W, Loew D: Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure. Ergebnisse einer Doppelblindstudie. MMW Munch Med Wochenschr 1980; 122: 795-798.
39. Smirne S: Triflusal in the prevention of cerebrovascular attacks. G Gerontol 1995; 43: 563-569.
40. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA: Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 1983; 14: 15-22.
41. Steiner M, Glantz M, Lekos A: Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62(6 suppl):1381S- 1384S.
42. Tohgi H, Murakami M: Pathophysiology and treatment of thrombosis. 2. The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study. Nippon Naika Gakkai Zasshi 1987; 76: 49-52.
43. Coull AJ, Lovett JK, Rothwell PM: Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326.
44. Johnston SC, Gress DR, Browner WS, Sidney S: Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-2906.
45. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 857-865.
46. Algra A, van Gijn J: Science unblinded. Lancet 1994; 343: 1040.
47. Howard SC, Algra A, Warlow CP, Rothwell PM: Potential consequences for recruitment, power, and external validity of requirements for additional risk factors for eligibility in randomized controlled trials in secondary prevention of stroke. Stroke 2006; 37: 209-215.
48. Rothwell PM: Making the most of secondary prevention. Stroke 2007; 38: 1726.
49. Kleindorfer D, Broderick J, Khoury J, Flaherty M, Woo D, Alwell K, Moomaw CJ, Schneider A, Miller R, Shukla R, Kissela B: The unchanging incidence and case-fatality of stroke in the 1990s: a population-based study. Stroke 2006; 37: 2473-2478. (Pubitemid 44454663)
50. Benatru I, Rouaud O, Durier J, Contegal F, Couvreur G, Bejot Y, Osseby GV, Ben Salem D, Ricolfi F, Moreau T, Giroud M: Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004. Stroke 2006; 37: 1674-1679.
51. Sivenius J, Tuomilehto J, Immonen-Raiha P, Kaarisalo M, Sarti C, Torppa J, Kuulasmaa K, Mahonen M, Lehtonen A, Salomaa V: Continuous 15-year decrease in incidence and mortality of stroke in Finland: the FINSTROKE study. Stroke 2004; 35: 420-425. (Pubitemid 38174423)
52. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P: Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933.
53. Carandang R, Seshadri S, Beiser A, Kelly- Hayes M, Kase CS, Kannel WB, Wolf PA: Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 2006; 296: 2939-2946.
54. Giles MF, Rothwell PM: Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6: 1063-1072.
55. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA: Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 2417-2422.
56. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.